CaltechAUTHORS
Published May 20, 2021 | Version Supplemental Material + Submitted
Journal Article Open

Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice

Creators

  • 1. ROR icon Institute of Molecular Genetics
  • 2. ROR icon Rockefeller University
  • 3. ROR icon Policlinico San Matteo Fondazione
  • 4. ROR icon Joint Research Centre
  • 5. ROR icon Veterinary Research Institute
  • 6. ROR icon Czech Academy of Sciences
  • 7. ROR icon University of South Bohemia in České Budějovice
  • 8. ROR icon Institute of Organic Chemistry and Biochemistry
  • 9. ROR icon Karolinska Institute
  • 10. ROR icon California Institute of Technology
  • 11. ROR icon University of Pavia

Abstract

Neutralizing antibodies that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein are among the most promising approaches against COVID-19. A bispecific IgG1-like molecule (CoV-X2) has been developed on the basis of C121 and C135, two antibodies derived from donors who had recovered from COVID-19. Here we show that CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, prevents detectable spike binding to the cellular receptor of the virus, angiotensin-converting enzyme 2 (ACE2). Furthermore, CoV-X2 neutralizes wild-type SARS-CoV-2 and its variants of concern, as well as escape mutants generated by the parental monoclonal antibodies. We also found that in a mouse model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, the simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, and combines the advantages of antibody cocktails with those of single-molecule approaches.

Additional Information

© The Author(s), under exclusive licence to Springer Nature Limited 2021. Received 07 January 2021; Accepted 16 March 2021; Published 25 March 2021. D.F.R., L.V., Q.P.-H., F.Baldanti and L.C. have received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 101003650. This work was also supported by SNF grant 31003A_182270 (L.V.); Lions Club Monteceneri (L.V.); George Mason University Fast Grant and IRB start-up funds (D.F.R.); NIH U01 AI151698 for the United World Antiviral Research Network (UWARN) (D.F.R. and M.C.N.); NIH grant P01-AI138398-S1 (M.C.N. and P.J.B.); 2U19AI111825 (M.C.N. and D.F.R.); the Caltech Merkin Institute for Translational Research and P50 AI150464 (P.J.B.); R37-AI64003 (P.D.B.); and R01AI78788 (T.H.); P.D.B. and M.C.N. are Howard Hughes Medical Institute Investigators. The study was also supported by the Czech Academy of Sciences and Czech Ministry of Agriculture (RVO 68378050 (R.S.) and RVO0518 (D.R.)); Czech Ministry of Education, Youth and Sports and the European Regional Development Fund (LM2018126; CZ.1.05/2.1.00/19.0395 and CZ.1.05/1.1.00/02.0109 (R.S.) and CZ.02.1.01/0.0/0.0/15_003/0000495 (D.R.)); Czech Science Foundation (20-14325S (D.R.)); the Bulgari Women & Science Fellowship in COVID-19 Research (F. Muecksch); the EU Joint Research Centre Exploratory Research program ('NanoMicrobials′; D. Magrì); and by Ricerca Finalizzata from Ministry of Health, Italy (grant no. GR-2013-02358399 (A.P.)). We are grateful for the high-performance computing resources that were provided by S. Bassini of CINECA to M. Hust, F. Bertoglio, F. Bognuda and E. Restivo. We thank V. Zatecka, V. Martinkova and L. Kutlikova for technical assistance; and V. Babak for help with statistical analyses. We are grateful to the late F. Diederich for their mentorship. Data availability: The data that support the findings of this study are available within the Article and its Supplementary Information. Any other data are available from the corresponding author upon reasonable request. Published data were taken from GenBank (https://www.ncbi.nlm.nih.gov/genbank/), UniProt (https://www.uniprot.org/), PDB (https://www.rcsb.org/) and the ViPR database (https://www.viprbrc.org/). Source data are provided with this paper. These authors contributed equally: Raoul De Gasparo, Mattia Pedotti. Author Contributions: R.D.G, M. Pedotti, L.S., F. Muecksch, J.C.C.L., F. Mazzola, D. Magrì, I.C., E.P., S.D.G., M. Palus, D. Mehn, S. Gioria, C.O.B., F. Bianchini, J.C.S., F.G. and S. Gaiarsa designed and carried out experiments and analysed results, and produced plasmids, antibodies and viral proteins. P.N., T.M., J.H., V.H, B.M., N.P., A.F., J.T., V.I., M. Palus, D.Z., P.B., I.B., P.S. and D.R., performed mouse experiments and analysed the results. L.V., D.F.R., D.R., Q.P.-H., F. Baldanti, A.P., L.C., P.J.B., M.C.N., P.D.B. and T.H. conceived and designed study and experiments, and analysed the results. P.N., T.M., R.N., O.P., J.P., J.R. and R.S. conceived and designed the mouse model. L.V., D.F.R., D.R. and R.D.G. wrote the manuscript, with input from all co-authors. Competing interests: The Institute for Research in Biomedicine has filed a provisional European patent application in connection with this work, on which L.V. is inventor (PCT/EP2020/085342). The Rockefeller University has filed a provisional US patent application (US 63/021,387) on coronavirus antibodies, on which D.F.R. and M.C.N. are inventors. Peer review information: Nature thanks Stanley Perlman and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Errata

In this Article, authors Raoul De Gasparo and Mattia Pedotti should not be linked to affiliation 15, 'Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA' and should instead be linked to the equal contribution footnote, 16. In addition, affiliation 14 should read 'Università degli Studi di Pavia, Pavia, Italy'. The Article has been corrected online. De Gasparo, R., Pedotti, M., Simonelli, L. et al. Publisher Correction: Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature (2021). https://doi.org/10.1038/s41586-021-03719-5

Attached Files

Submitted - 20210122-427567v2.full.pdf

Supplemental Material - 41586_2021_3461_Fig10_ESM.webp

Supplemental Material - 41586_2021_3461_Fig3_ESM.webp

Supplemental Material - 41586_2021_3461_Fig4_ESM.webp

Supplemental Material - 41586_2021_3461_Fig5_ESM.webp

Supplemental Material - 41586_2021_3461_Fig6_ESM.webp

Supplemental Material - 41586_2021_3461_Fig7_ESM.webp

Supplemental Material - 41586_2021_3461_Fig8_ESM.webp

Supplemental Material - 41586_2021_3461_Fig9_ESM.webp

Supplemental Material - 41586_2021_3461_MOESM1_ESM.pdf

Supplemental Material - 41586_2021_3461_MOESM2_ESM.pdf

Supplemental Material - 41586_2021_3461_MOESM3_ESM.xlsx

Supplemental Material - 41586_2021_3461_Tab1_ESM.jpg

Files

20210122-427567v2.full.pdf

Files (25.9 MB)

Name Size Download all
md5:a5bf2cb71f28693149c08504ef7a6915
12.7 MB Preview Download
md5:c83dfcb3950823aace806bc69f097709
319.6 kB Preview Download
md5:1c074f0fad4d399f29b0055dd7725e30
50.3 kB Preview Download
md5:be6c4befa7a3f977a41b4cd4f20c7010
364.2 kB Preview Download
md5:a51326e21dcc84b2625494b74722d233
75.0 kB Preview Download
md5:6d80cfb36600a30b47a25e4386e65235
154.9 kB Preview Download
md5:5e4660631fb732d7c7dcc1065e97cd62
103.1 kB Preview Download
md5:709094f8abb1aefaedc2c19fcbe5a16b
366.8 kB Preview Download
md5:6965d6a0f09aa6387c5e38161f2ebeec
551.1 kB Preview Download
md5:4fc0ceee32ca55f3c98fe6563ef120ab
8.5 MB Preview Download
md5:17efbdfd15e67343124f1ddfe33d51d7
2.6 MB Preview Download
md5:81b8855a7766f441fdabb2526daaedc2
21.3 kB Download
md5:ddb85452e422307736bda34d84d13788
16.9 kB Preview Download

Additional details

Additional titles

Alternative title
Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease

Identifiers

PMCID
PMC8330819
Eprint ID
108344
DOI
10.1038/s41586-021-03461-y
Resolver ID
CaltechAUTHORS:20210308-130543968

Related works

Describes
10.1038/s41586-021-03719-5 (DOI)
10.1101/2021.01.22.427567 (DOI)

Funding

European Research Council (ERC)
101003650
Swiss National Science Foundation (SNSF)
31003A_182270
Lions Club Monteceneri
George Mason University
NIH
U01 AI151698
NIH
P01-AI138398-S1
NIH
2U19AI111825
Caltech Merkin Institute for Translational Research
NIH
P50 AI150464
NIH
R37-AI64003
NIH
R01AI78788
Howard Hughes Medical Institute (HHMI)
Czech Academy of Sciences
Ministry of Agriculture (Czech Republic)
RVO 68378050
Ministry of Agriculture (Czech Republic)
RVO0518
Ministry of Education, Youth and Sports (Czech Republic)
European Regional Development Fund
LM2018126
European Regional Development Fund
CZ.1.05/2.1.00/19.0395
European Regional Development Fund
CZ.1.05/1.1.00/02.0109
European Regional Development Fund
CZ.02.1.01/0.0/0.0/15_003/0000495
Czech Science Foundation
20-14325S
Bulgari Women & Science Fellowship in COVID-19 Research
European Union Joint Research Centre Exploratory Research Program
Ricerca Finalizzata
GR-2013-02358399
Ministero della Salute (Italy)

Dates

Created
2021-03-08
Created from EPrint's datestamp field
Updated
2023-10-02
Created from EPrint's last_modified field

Caltech Custom Metadata

Caltech groups
COVID-19, Richard N. Merkin Institute for Translational Research, Division of Biology and Biological Engineering (BBE)